ObjectiveThe aim of the study was to determine whether type II endoleak (T2E) after endovascular repair of abdominal aorta (EVAR) is a benign condition (ie, not associated with growth, reintervention, rupture, or death).MethodsData from patients who underwent EVAR for atherosclerotic infrarenal aortic aneurysms between June 1995 and May 2010 in the Vascular Surgery Department of Henri Mondor Hospital were prospectively collected. Data from patients presenting with at least one T2E on computed tomography scan during their follow-up were compared with those with no T2E. Three subcategories of T2E were studied according to time of occurrence (early or late), persistence (persistent or transient), and recurrence (recurrent or not recurrent).Res...
BACKGROUND: Persistent type II endoleaks (ELIIp, 656 months) after an endovascular aneurysm repair ...
PurposeMost clinical end points after endovascular aneurysm repair (EVAR) are endograft-specific, bu...
AbstractObjective. There is still debate whether type II endoleaks represent a risk for the patient ...
Aim: The incidence for type II endoleaks (T2E) reported in literature varies between 10% and 20% but...
Aim: The incidence for type II endoleaks (T2E) reported in literature varies between 10% and 20% but...
ObjectiveThe treatment of type II endoleaks remains controversial because little is known about thei...
ObjectiveType II endoleak is the most common complication after endovascular abdominal aortic aneury...
AbstractObjective: The purpose of this study was to evaluate the effect of preoperative coil emboliz...
Purpose: To evaluate the frequency of type II endoleaks after endovascular aneurysm repair (EVAR) an...
OBJECTIVES:This systematic review and meta-analysis aims to determine the current evidence on risk f...
Summary: Background/Objectives: The natural history of type II endoleaks (T2ELs) is still not compl...
Type II endoleak is increasingly seen as a benign, fre-quently self-healing event and its significan...
BACKGROUND: Persistent type II endoleaks (ELIIp, â¥6 months) after an endovascular aneurysm repair (...
AbstractObjective. There is still debate whether type II endoleaks represent a risk for the patient ...
AbstractObjectiveEndovascular repair (EVAR) of abdominal aortic aneurysms (AAAs) has led to a reduct...
BACKGROUND: Persistent type II endoleaks (ELIIp, 656 months) after an endovascular aneurysm repair ...
PurposeMost clinical end points after endovascular aneurysm repair (EVAR) are endograft-specific, bu...
AbstractObjective. There is still debate whether type II endoleaks represent a risk for the patient ...
Aim: The incidence for type II endoleaks (T2E) reported in literature varies between 10% and 20% but...
Aim: The incidence for type II endoleaks (T2E) reported in literature varies between 10% and 20% but...
ObjectiveThe treatment of type II endoleaks remains controversial because little is known about thei...
ObjectiveType II endoleak is the most common complication after endovascular abdominal aortic aneury...
AbstractObjective: The purpose of this study was to evaluate the effect of preoperative coil emboliz...
Purpose: To evaluate the frequency of type II endoleaks after endovascular aneurysm repair (EVAR) an...
OBJECTIVES:This systematic review and meta-analysis aims to determine the current evidence on risk f...
Summary: Background/Objectives: The natural history of type II endoleaks (T2ELs) is still not compl...
Type II endoleak is increasingly seen as a benign, fre-quently self-healing event and its significan...
BACKGROUND: Persistent type II endoleaks (ELIIp, â¥6 months) after an endovascular aneurysm repair (...
AbstractObjective. There is still debate whether type II endoleaks represent a risk for the patient ...
AbstractObjectiveEndovascular repair (EVAR) of abdominal aortic aneurysms (AAAs) has led to a reduct...
BACKGROUND: Persistent type II endoleaks (ELIIp, 656 months) after an endovascular aneurysm repair ...
PurposeMost clinical end points after endovascular aneurysm repair (EVAR) are endograft-specific, bu...
AbstractObjective. There is still debate whether type II endoleaks represent a risk for the patient ...